CVS Caremark, Generation Health to Expand PGx Testing to Millions | GenomeWeb

NEW YORK (GenomeWeb News) – CVS Caremark the country’s largest pharmacy services provider, has decided to expand pharmacogenomic testing to its pharmacy benefit management customers to predict their responses to treatments for cancer, cardiovascular diseases, and HIV.

Generation Health, a company launched last year to help insurers, employers, and PBMs implement genetic testing with their systems, will help CVS Caremark put its pharmacogenomics testing programs in place, the companies said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.